Skip to main content
Top
Published in: Dermatology and Therapy 3/2016

Open Access 01-09-2016 | Original Research

Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients

Authors: Marianne Lind, Kim Troensegaard Nielsen, Line Hollesen Schefe, Kasper Nørremark, André Huss Eriksson, Hanne Norsgaard, Brian Thoning Pedersen, Karsten Petersson

Published in: Dermatology and Therapy | Issue 3/2016

Login to get access

Abstract

Introduction

Previous studies have demonstrated the superior efficacy of a novel aerosol foam formulation of fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064% (BD), compared with the ointment formulation. The aim of this study is to ascertain whether enhanced bioavailability of the active ingredients due to supersaturation and/or occlusive properties can explain the observed greater clinical efficacy.

Methods

Solubility and evaporation experiments were conducted to examine the abilities of Cal/BD aerosol foam ingredients to create a supersaturated environment. Optical microscopy, Raman imaging and X-ray powder diffraction were used to examine the physical state of Cal and BD in the formulations after application, and determine whether a supersaturated state remained stable for clinically relevant time periods. In vitro skin penetration and ex vivo biomarker assays were conducted to compare the skin penetration and bioavailability of Cal and BD from the aerosol foam and ointment formulations, respectively. Occlusive properties were examined via transepidermal water loss.

Results

Solubility studies showed that Cal and BD solubility increased with increasing dimethyl ether (DME) content. Both active ingredients are completely dissolved in the final aerosol foam formulation. DME rapidly evaporates after spraying, and the amount was reduced to 0.5% of the initial amount after 2 min. This led to the formation of a supersaturated environment, where Cal and BD crystals were absent for at least 26 h after application. Cal/BD aerosol foam had significantly greater in vitro skin penetration and had increased bioavailability compared with Cal/BD ointment. Both formulations effectively occluded the skin.

Conclusion

A stable supersaturated solution of Cal/BD in the aerosol foam leads to increased bioavailability and explains the improved clinical effect when compared to the Cal/BD ointment.

Funding

The studies included in the paper are all conducted by LEO Pharma A/S or CROs on behalf of LEO Pharma A/S.
Literature
1.
go back to reference Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.CrossRefPubMed Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.CrossRefPubMed
3.
go back to reference Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.CrossRefPubMed Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.CrossRefPubMed
4.
5.
go back to reference Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168:20–31.CrossRefPubMed Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168:20–31.CrossRefPubMed
6.
go back to reference Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009–16.CrossRefPubMed Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009–16.CrossRefPubMed
7.
go back to reference Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology. 2005;210:157–68.CrossRefPubMed Surber C, Smith EW. The mystical effects of dermatological vehicles. Dermatology. 2005;210:157–68.CrossRefPubMed
8.
go back to reference Hollesen Basse L, Olesen M, Lacour JP, Queille-Roussel C. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134:S33 (abst 192). Hollesen Basse L, Olesen M, Lacour JP, Queille-Roussel C. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134:S33 (abst 192).
9.
go back to reference Queille-Roussel C, Olesen M, Villumsen J, Lacour JP. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015;35:239–45.CrossRefPubMedPubMedCentral Queille-Roussel C, Olesen M, Villumsen J, Lacour JP. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015;35:239–45.CrossRefPubMedPubMedCentral
10.
go back to reference Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris—a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14:1468–77.PubMed Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris—a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14:1468–77.PubMed
11.
go back to reference Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2015;20:44–51.CrossRefPubMed Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2015;20:44–51.CrossRefPubMed
12.
go back to reference Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase II study. J Clin Aesthet Dermatol. 2016;9:34–41. Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase II study. J Clin Aesthet Dermatol. 2016;9:34–41.
13.
go back to reference Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—a randomized phase II study. J Dermatolog Treat. 2016;27:120–7.CrossRefPubMed Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—a randomized phase II study. J Dermatolog Treat. 2016;27:120–7.CrossRefPubMed
14.
go back to reference Paul C, Stein Gold L, Warren RB, et al. Superior efficacy of the fixed combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel, in patients with psoriasis vulgaris—the phase III PSO-ABLE study. In: 24th Congress of the European academy of dermatology and venereology. Copenhagen, Denmark, 7–11 October 2015: abst COP15-1087. Paul C, Stein Gold L, Warren RB, et al. Superior efficacy of the fixed combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel, in patients with psoriasis vulgaris—the phase III PSO-ABLE study. In: 24th Congress of the European academy of dermatology and venereology. Copenhagen, Denmark, 7–11 October 2015: abst COP15-1087.
15.
go back to reference Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):36–46.CrossRefPubMed Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):36–46.CrossRefPubMed
16.
go back to reference Hadgraft J, Lane ME. Drug crystallization-implications for topical and transdermal delivery. Expert Opin Drug Deliv. 2016;6:817–30. Hadgraft J, Lane ME. Drug crystallization-implications for topical and transdermal delivery. Expert Opin Drug Deliv. 2016;6:817–30.
17.
go back to reference Marks R. The stratum corneum barrier: the final frontier. J Nutr. 2004;134:2017S–21S.PubMed Marks R. The stratum corneum barrier: the final frontier. J Nutr. 2004;134:2017S–21S.PubMed
18.
go back to reference Barrett CW, Hadgraft JW, Caron GA, Sarkany I. The effect of particle size and vehicle on the percutaneous absorption of fluocinolone acetonide. Br J Dermatol. 1965;77:576–8.CrossRefPubMed Barrett CW, Hadgraft JW, Caron GA, Sarkany I. The effect of particle size and vehicle on the percutaneous absorption of fluocinolone acetonide. Br J Dermatol. 1965;77:576–8.CrossRefPubMed
19.
go back to reference Ghafourian T, Samaras EG, Brooks JD, Riviere JE. Validated models for predicting skin penetration from different vehicles. Eur J Pharm Sci. 2010;41:612–6.CrossRefPubMed Ghafourian T, Samaras EG, Brooks JD, Riviere JE. Validated models for predicting skin penetration from different vehicles. Eur J Pharm Sci. 2010;41:612–6.CrossRefPubMed
20.
go back to reference Santos P, Watkinson AC, Hadgraft J, Lane ME. Enhanced permeation of fentanyl from supersaturated solutions in a model membrane. Int J Pharm. 2011;407:72–7.CrossRefPubMed Santos P, Watkinson AC, Hadgraft J, Lane ME. Enhanced permeation of fentanyl from supersaturated solutions in a model membrane. Int J Pharm. 2011;407:72–7.CrossRefPubMed
21.
go back to reference Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res. 1996;13:1765–9.CrossRefPubMed Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res. 1996;13:1765–9.CrossRefPubMed
22.
go back to reference Barry BW. Mode of action of penetration enhancers in human skin. J Control Release. 1987;6:85–97.CrossRef Barry BW. Mode of action of penetration enhancers in human skin. J Control Release. 1987;6:85–97.CrossRef
23.
go back to reference Smith EW, Maibach HI. Future perspectives for penetration enhancers. In: Smith EW, Maibach HI, editors, Percutaneous penetration enhancers. Boca Raton: CRC Press; 1995. p. 481–484. Smith EW, Maibach HI. Future perspectives for penetration enhancers. In: Smith EW, Maibach HI, editors, Percutaneous penetration enhancers. Boca Raton: CRC Press; 1995. p. 481–484.
24.
go back to reference Moser K, Kriwet K, Froehlich C, Kalia YN, Guy RH. Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug. Pharm Res. 2001;18:1006–11.CrossRefPubMed Moser K, Kriwet K, Froehlich C, Kalia YN, Guy RH. Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug. Pharm Res. 2001;18:1006–11.CrossRefPubMed
25.
go back to reference Woodford R, Barry BW. Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam. J Pharm Sci. 1977;66:99–103.CrossRefPubMed Woodford R, Barry BW. Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam. J Pharm Sci. 1977;66:99–103.CrossRefPubMed
26.
go back to reference Coldman MF, Poulsen BJ, Higuchi T. Enhancement of percutaneous absorption by the use of volatile: nonvolatile systems as vehicles. J Pharm Sci. 1969;58:1098–102.CrossRefPubMed Coldman MF, Poulsen BJ, Higuchi T. Enhancement of percutaneous absorption by the use of volatile: nonvolatile systems as vehicles. J Pharm Sci. 1969;58:1098–102.CrossRefPubMed
27.
go back to reference Schaefer H, Redelmeier TE. Skin barrier: principles of percutaneous absorption. New York: Karger; 1996. Schaefer H, Redelmeier TE. Skin barrier: principles of percutaneous absorption. New York: Karger; 1996.
28.
go back to reference Bjorklund S, Engblom J, Thuresson K, Sparr E. A water gradient can be used to regulate drug transport across skin. J Control Release. 2010;143:191–200.CrossRefPubMed Bjorklund S, Engblom J, Thuresson K, Sparr E. A water gradient can be used to regulate drug transport across skin. J Control Release. 2010;143:191–200.CrossRefPubMed
29.
go back to reference Zhai H, Maibach HI. Effects of skin occlusion on percutaneous absorption: an overview. Skin Pharmacol Appl Skin Physiol. 2001;14:1–10.CrossRefPubMed Zhai H, Maibach HI. Effects of skin occlusion on percutaneous absorption: an overview. Skin Pharmacol Appl Skin Physiol. 2001;14:1–10.CrossRefPubMed
30.
go back to reference Iervolino M, Cappello B, Raghavan SL, Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm. 2001;212:131–41.CrossRefPubMed Iervolino M, Cappello B, Raghavan SL, Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm. 2001;212:131–41.CrossRefPubMed
Metadata
Title
Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients
Authors
Marianne Lind
Kim Troensegaard Nielsen
Line Hollesen Schefe
Kasper Nørremark
André Huss Eriksson
Hanne Norsgaard
Brian Thoning Pedersen
Karsten Petersson
Publication date
01-09-2016
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 3/2016
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-016-0125-6

Other articles of this Issue 3/2016

Dermatology and Therapy 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine